Bonelli Raphael M, Niederwieser Gerald, Lahousen Theresa, Hofmann Peter
Department of Neurology and Psychiatry, Hospital BHB Eggenberg, Bergstrasse 27, A-8021 Graz, Austria.
Hum Psychopharmacol. 2003 Apr;18(3):227-9. doi: 10.1002/hup.474.
The authors report a patient with Huntington's disease (HD) presenting with severe chorea. The motor scale of the unified HD rating scale (UHDRS-I) revealed 81 points. Motor function clearly improved with zotepine, until she reached an UHDRS-I of 34 points on day 7 of treatment. The patient was stable for at least 12 weeks. The improvement includes all seven categories of the UHDRS-I, especially chorea, gait and oral function. This is the first description of zotepine in HD. Our findings suggest that zotepine is useful in the treatment of HD chorea. Controlled trials of its use in HD would be welcome.
作者报告了一名患有亨廷顿舞蹈病(HD)且伴有严重舞蹈症的患者。统一亨廷顿舞蹈病评定量表(UHDRS - I)的运动评分显示为81分。使用佐替平后运动功能明显改善,在治疗第7天时UHDRS - I评分降至34分。该患者病情稳定至少12周。改善涵盖了UHDRS - I的所有七个类别,尤其是舞蹈症、步态和口腔功能。这是关于佐替平治疗亨廷顿舞蹈病的首次描述。我们的研究结果表明佐替平在治疗HD舞蹈症方面有效。欢迎开展关于其在HD中应用的对照试验。